tiprankstipranks
Morepen Laboratories Limited (IN:MOREPENLAB)
:MOREPENLAB
India Market
Want to see IN:MOREPENLAB full AI Analyst Report?

Morepen Laboratories Limited (MOREPENLAB) Price & Analysis

14 Followers

MOREPENLAB Stock Chart & Stats

₹41.99
-₹1.18(-1.56%)
At close: 4:00 PM EST
₹41.99
-₹1.18(-1.56%)

Bulls Say, Bears Say

Bulls Say
Diversified Revenue Streams (APIs, Formulations, Consumer)A multi-pronged business model (APIs, finished formulations, consumer health) reduces concentration risk and provides multiple channels for growth. Durable demand across B2B API contracts, institutional formulations and consumer retail supports more stable revenue mix over the medium term.
Improved Profitability And Sustained Net Income Since 2024Restored profitability and consistent net income since 2024 indicate operational recovery and better cost control. Sustained positive earnings provide a foundation for reinvestment, margin resilience, and potential deleveraging if cash conversion trends improve.
Balance Sheet Supported By Growing Equity And Moderate LeverageA rising equity base and moderate leverage provide financial cushioning versus peers, preserving capacity to access capital or fund strategic investments. This structural buffer improves resilience to cyclical stress and supports longer-term operational planning.
Bears Say
Weak Cash Conversion; Negative Free Cash Flow 2024–2026Persistent negative free cash flow despite positive earnings signals weak earnings quality and limits internal funding. Over the medium term this constrains capex, dividend capacity and debt reduction, and elevates reliance on external financing to support growth or working capital.
Material Rise In Total Debt In 2026A notable increase in debt in 2026 reduces financial flexibility and raises interest and covenant risk. Even with moderate overall leverage, a recent uptick in debt can constrain strategic options and increase cash demands, making the business more sensitive to cash-flow volatility.
Revenue Momentum Cooled And Margins Compressed In 2026A pause in revenue growth alongside margin compression suggests rising cost pressure or weaker pricing power. Over the medium term this can limit earnings upside and slow return on equity recovery, increasing execution risk for margin restoration and sustainable growth.

MOREPENLAB FAQ

What was Morepen Laboratories Limited’s price range in the past 12 months?
Morepen Laboratories Limited lowest stock price was ₹33.42 and its highest was ₹64.57 in the past 12 months.
    What is Morepen Laboratories Limited’s market cap?
    Morepen Laboratories Limited’s market cap is ₹31.23B.
      When is Morepen Laboratories Limited’s upcoming earnings report date?
      Morepen Laboratories Limited’s upcoming earnings report date is Aug 04, 2026 which is today.
        How were Morepen Laboratories Limited’s earnings last quarter?
        Morepen Laboratories Limited released its earnings results on May 26, 2026. The company reported ₹0.28 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
          Is Morepen Laboratories Limited overvalued?
          According to Wall Street analysts Morepen Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Morepen Laboratories Limited pay dividends?
            Morepen Laboratories Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.35%. See more information on Morepen Laboratories Limited dividends here
              What is Morepen Laboratories Limited’s EPS estimate?
              Morepen Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Morepen Laboratories Limited have?
              Morepen Laboratories Limited has 547,953,700 shares outstanding.
                What happened to Morepen Laboratories Limited’s price movement after its last earnings report?
                Morepen Laboratories Limited reported an EPS of ₹0.28 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.503%.
                  Which hedge fund is a major shareholder of Morepen Laboratories Limited?
                  Currently, no hedge funds are holding shares in IN:MOREPENLAB
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Morepen Laboratories Limited

                    Morepen Laboratories Limited is an Indian pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), proprietary and generic pharmaceutical formulations, and a diverse range of home healthcare products. Its API portfolio encompasses compounds utilized in the creation of drugs for conditions such as allergies, asthma, elevated cholesterol, hypertension, and diabetes. The company also supplies an array of point-of-care and medical devices for home use, including diagnostic tools like air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse oximeters, nebulizers, glucometers with accompanying strips, as well as hygiene products such as sanitizers, disinfectant solutions, masks, and gloves. Among its well-known branded products are Burnol, a cream for treating burns; Lemolate, an offering for cough and cold relief; and Fiber-X, a psyllium husk supplement. Furthermore, Morepen produces finished drug formulations covering various therapeutic areas, including gastrointestinal health, antibiotics, vitamins, nutritional support, anti-diabetics, and cardiovascular conditions. Beyond these offerings, the company undertakes contract manufacturing for other businesses and participates in brand sharing agreements. Its comprehensive range of over-the-counter (OTC) products is marketed under the recognizable Dr. Morepen brand. The company's global footprint extends to approximately 75 nations, where its products are exported. Established in 1984, Morepen Laboratories Limited maintains its headquarters in New Delhi, India.

                    Morepen Laboratories Limited (MOREPENLAB) Earnings & Revenues

                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Alembic Limited
                    Hikal Limited
                    Indoco Remedies Limited
                    Solara Active Pharma Sciences Ltd.
                    Windlas Biotech Ltd.
                    Popular Stocks